A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)

Trial Profile

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ZUMA-2
  • Sponsors Kite Pharma
  • Most Recent Events

    • 03 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2018.
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
    • 07 Oct 2016 According to a Kite Pharma media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) annual congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top